Format

Send to

Choose Destination
BMC Cancer. 2018 Mar 7;18(1):262. doi: 10.1186/s12885-018-4158-3.

Burden of early, advanced and metastatic breast cancer in The Netherlands.

Author information

1
Department of Pharmaco-Epidemiology and Economics, University of Groningen, PO Box 72, Groningen, 9700 AB, The Netherlands. gertvondeling@msn.com.
2
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
3
Department of Pharmaco-Epidemiology and Economics, University of Groningen, PO Box 72, Groningen, 9700 AB, The Netherlands.
4
Department of Clinical Pharmacy, Deventer Hospital, Deventer, The Netherlands.
5
Groningen Research Institute of Pharmacy, PharmacoTherapy, - Epidemiology & -Economics University of Groningen, Groningen, The Netherlands.
6
Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
7
Department of Public Affairs, Pfizer, Rotterdam, The Netherlands.

Abstract

BACKGROUND:

The aim of this study was to estimate the total economic and health related burden of breast cancer in the Netherlands.

METHODS:

Data on incidence, prevalence, mortality and survival were extracted from the Dutch National Cancer Registry and were used to calculate the economic and health related burden of breast cancer for overall, DCIS (stage 0), early- (stage I), locally advanced- (stage II-III) and metastatic- (stage IV) breast cancer by age groups and by year (if applicable).

RESULTS:

The overall incidence of breast cancer increased from 103.4 up to 153.2 per 100,000 women between 1990 and 2014. The increase was driven by DCIS and early breast cancer as the incidence of locally advanced and metastatic breast cancer remained stable. Between 1990 and 2014, ten-year overall survival rates increased from 87% to 93% for early breast cancer, 41% to 62% for locally advanced- and from 6% to 9% for metastatic disease. Annually, breast cancer in the Netherlands is responsible for approximately 3100 deaths, 26,000 life years lost, 65,000 Disability Adjusted Life Years (DALYs) and an economic burden of €1.27 billion.

CONCLUSIONS:

This study provides a comprehensive assessment of the burden of breast cancer and subsequent trends over time in the Netherlands.

KEYWORDS:

Breast cancer burden costs incidence prevalence mortality early advanced metastatic

PMID:
29514651
PMCID:
PMC5842550
DOI:
10.1186/s12885-018-4158-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center